2025 North America Allergy Diagnostics Market Revenue Opportunities Report
Description
The 2025 North America Allergy Diagnostics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Diagnostics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American allergy diagnostics market are Thermo Fisher Scientific Inc., Danaher Corporation, Siemens Healthineers AG, and Minaris Medical America, Inc. Thermo Fisher Scientific, headquartered in the U.S., holds a dominant position with its widely used Phadia allergy testing systems, serving over 400,000 clients across various healthcare and research sectors, and recently expanded its Phadia 2500+ series in the U.S. Danaher, also U.S.-based, leads in market share by leveraging a broad portfolio and strong presence. Siemens Healthineers (Germany) is another key player known for advanced diagnostic technologies. Minaris Medical America, a U.S. subsidiary of Canon (Japan), is recognized for multiplex in vitro allergy testing products like the OPTIGEN Allergen-Specific IgE Assay, supporting environmental and dietary allergen diagnostics.
These companies focus on innovation and expanding their portfolios to address rising allergy prevalence in North America, where the market accounted for over 36% of global share in 2024. They emphasize advancements such as multiplex testing, automated high-throughput instruments, and personalized immunotherapies. The U.S. market is driven by increasing allergy awareness, government initiatives, and robust biotechnology infrastructure. Consumables generate the largest revenue segment, while hospital-based laboratories lead end-user segments. Strategic collaborations with academic institutions and investments in research and development enable these firms to maintain competitive positions and support the growing demand for accurate and efficient allergy diagnostics throughout North America.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Diagnostics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American allergy diagnostics market are Thermo Fisher Scientific Inc., Danaher Corporation, Siemens Healthineers AG, and Minaris Medical America, Inc. Thermo Fisher Scientific, headquartered in the U.S., holds a dominant position with its widely used Phadia allergy testing systems, serving over 400,000 clients across various healthcare and research sectors, and recently expanded its Phadia 2500+ series in the U.S. Danaher, also U.S.-based, leads in market share by leveraging a broad portfolio and strong presence. Siemens Healthineers (Germany) is another key player known for advanced diagnostic technologies. Minaris Medical America, a U.S. subsidiary of Canon (Japan), is recognized for multiplex in vitro allergy testing products like the OPTIGEN Allergen-Specific IgE Assay, supporting environmental and dietary allergen diagnostics.
These companies focus on innovation and expanding their portfolios to address rising allergy prevalence in North America, where the market accounted for over 36% of global share in 2024. They emphasize advancements such as multiplex testing, automated high-throughput instruments, and personalized immunotherapies. The U.S. market is driven by increasing allergy awareness, government initiatives, and robust biotechnology infrastructure. Consumables generate the largest revenue segment, while hospital-based laboratories lead end-user segments. Strategic collaborations with academic institutions and investments in research and development enable these firms to maintain competitive positions and support the growing demand for accurate and efficient allergy diagnostics throughout North America.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
